● pepmg Research Desk · Peer-reviewed evidence review
What the research says about FOXO4-DRI
A neutral summary of the peer-reviewed literature on FOXO4-DRI, a synthetic senolytic peptide designed to disrupt the FOXO4-p53 interaction and trigger death of senescent cells. All evidence to date is in cells and animals. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- FOXO4-DRI is a synthetic senolytic peptide: a D-retro-inverso version of a FOXO4 sequence, designed to block the FOXO4-p53 interaction so that p53 is excluded from the nucleus and senescent cells undergo apoptosis [1][2].
- In the foundational study it was reported to selectively kill senescent cells and, in fast-aging and naturally aged mice, to restore fitness, fur density, and renal function [2].
- All of the evidence is in cell and animal models. No controlled human trials of FOXO4-DRI appear in this corpus, and one animal study found that clearing senescent cells (including with FOXO4-DRI) could promote pulmonary hypertension [7].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What FOXO4-DRI is
FOXO4-DRI is described in the literature as a designed peptide that interferes with the interaction between the transcription factor FOXO4 and the tumor-suppressor protein p53. In senescent cells, FOXO4 is reported to bind p53 in the nucleus and keep those cells alive by suppressing apoptosis; the peptide disrupts that binding, causing p53 nuclear exclusion and cell-intrinsic apoptosis selectively in senescent cells [1][2]. The "DRI" refers to its D-retro-inverso construction, a mirror-image peptide chemistry intended to resist degradation, and it carries a cationic cell-permeability sequence to enter cells [6].
It emerged from work identifying FOXO4 as a pivot in senescent-cell viability: researchers designed a FOXO4 peptide to perturb the FOXO4-p53 interaction, then tested it as a senolytic (a compound that clears senescent cells) [2]. Structural studies have since mapped how the peptide engages the disordered p53 transactivation domain [6]. FOXO4-DRI has never been an approved medicine, and material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the preclinical research has measured
Preclinical onlyThe central report designed the FOXO4 peptide, showed that in senescent cells it selectively caused p53 nuclear exclusion and apoptosis, and then tested it in animals: under conditions where it was well tolerated in vivo, it was reported to neutralize doxorubicin-induced chemotoxicity and to restore fitness, fur density, and renal function in both fast-aging and naturally aged mice [2]. This work is in mice and cultured cells, not humans.
Subsequent studies applied FOXO4-DRI to specific tissues, all in cell or animal models. In naturally aged mice, FOXO4-DRI was reported to induce apoptosis of senescent Leydig cells and to alleviate age-related declines in testosterone and in spermatogenesis and sperm quality [4][5]. In human keloid (scar) fibroblast cultures and organ cultures, the peptide was reported to promote apoptosis of senescent fibroblasts [3]. These records are MeSH-indexed as human because they use human cells or human tissue samples, but they are laboratory studies, not clinical trials in people.
A separate line of structural and mechanistic work characterized the FOXO4-p53 axis and the peptide's binding in molecular detail, providing a basis for designing senescence-targeting inhibitors [1][6]. Across the corpus, the FOXO4-DRI literature is mechanistic and preclinical; it does not include controlled trials measuring clinical outcomes in humans.
What the studies report on safety and adverse events
Preclinical onlyBecause there are no human trials of FOXO4-DRI in this corpus, there is no controlled human safety or adverse-event data to report. The foundational animal work stated only that the peptide was tested under conditions where it was well tolerated in vivo in mice [2], which is a narrow statement about a specific mouse experiment, not a characterization of safety in people.
One animal study is an explicit caution. Investigating senescent cells in pulmonary hypertension, it found that clearing senescent cells, using genetic tools and senolytic drugs including FOXO4-DRI, could promote pulmonary hypertension development in mouse and rat models [7]. This illustrates that broadly eliminating senescent cells is not uniformly beneficial and can have adverse consequences depending on tissue and context.
None of this is a safety guarantee, in either direction. FOXO4-DRI is an experimental peptide with no controlled human safety evaluation here, and material sold by research-chemical vendors is not manufactured to pharmacy standards. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as preclinical. FOXO4-DRI has a well-defined molecular mechanism and a consistent set of cell and animal findings suggesting it can selectively drive senescent cells into apoptosis and, in aged mice, improve certain markers of tissue function [2][4][5]. What is entirely absent from this corpus is controlled human data: no clinical trials establish whether these effects, or any risks such as the pulmonary-hypertension signal [7], translate to people.
"Preclinical" is the honest ceiling here, and it is a strict one: promising mechanism and animal results are not evidence of human benefit or safety. Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 7
- Regulation of cellular senescence via the FOXO4-p53 axis.
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of p53.
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype.
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic peptide FOXO4-DRI.
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.